Cidara Therapeutics Announces Late-Breaking Phase 2b Data Presentation on CD388 at ID Week 2025
SAN DIEGO, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company applying its proprietary Cloudbreak®...
SAN DIEGO, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company applying its proprietary Cloudbreak®...
CHATHAM, N.J., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully-integrated,...
Seven-month extension valued at up to approximately $1.8 million CAD supports further evaluation as RDT advances broader commercialization initiatives for...
SHELTON, CT / ACCESS Newswire / October 20, 2025 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the "Company"),...
CAMBRIDGE, MA / ACCESS Newswire / October 19, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced data regarding two of its...
BOSTON, Oct. 17, 2025 /PRNewswire/ -- The seventh annual STAT Summit kicked off Wednesday in Boston, bringing together a carefully curated...
Elevate your services and maximize profits with the BeneLift® Pro - the next evolution in professional skincare technology. BOCA RATON,...
Backed by a $7.8M award from the National Science Foundation, Caravel unlocksbreakthroughs across animal health, biochemical manufacturing, and beyond. PORTLAND,...
CAMBRIDGE, MA / ACCESS Newswire / October 16, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that it will host a...
With more than 2,000 citations and year-over-year growth nearing 80%, TriNetX outpaces competitors and fuels high-impact science published in top...
NEW YORK, Oct. 15, 2025 /PRNewswire/ -- The Global Digital Health Market is projected to grow from USD 288.55 billion in...
Zaltenibart has best-in-class potential across multiple rare blood and kidney disorders and will enhance Novo Nordisk’s Rare Disease portfolioOmeros is...
Prestigious European Society for Medical Oncology Conference “trials-in-progress” session Pivotal OVATION 3 trial of its DNA-mediated immunotherapy in newly diagnosed...
Greater than 90% depletion of B cells within 12 hours of a single dose of AAN-14xMultiple redosing of AAN-14x at...
Automation-compatible, safe assay delivers same-day results to accelerate vaccine and therapeutic antibody development PHILADELPHIA, Oct. 14, 2025 /PRNewswire/ -- Integral...
AUSTIN, Texas and TOKYO, Oct. 13, 2025 /PRNewswire/ -- The global nanomedicine market size reached US$ 169.51 Billion in 2024...
Presentation will cover two-year clinical efficacy, immunogenicity and safety dataData will be presented at an oral session on October 17,...
EXECUTIVE CHAIRMAN & CEO OF MEDICUS TO PARTICIPATE IN A FIRESIDE CHAT WITH EQUITY RESEARCH ANALYST PHILADELPHIA, PENNSYLVANIA / ACCESS...
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE...
mRNA-4359 has advanced into the Phase 2 portion of the ongoing Phase 1/2 trial CAMBRIDGE, MA / ACCESS Newswire /...